Cover Image
市場調查報告書

全球癌症免疫療法市場:2016∼2020年

Global Cancer Immunotherapies Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 357353
出版日期 內容資訊 英文 121 Pages
訂單完成後即時交付
價格
Back to Top
全球癌症免疫療法市場:2016∼2020年 Global Cancer Immunotherapies Market 2016-2020
出版日期: 2016年04月27日 內容資訊: 英文 121 Pages
簡介

免疫療法副作用很少,可治療各種癌症。癌症的免疫療法佔癌症治療藥近50%。全球癌症免疫療法市場,預計2016∼2020年,以年複合成長率15.17%擴大。

本報告提供全球癌症免疫療法市場現狀與至2020年的成長預測,市場趨勢與課題,各地區趨勢,主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 癌症免疫療法概要

  • 流行病學
  • 癌症的費用
  • 癌症治療成本
  • 償付政策
  • 癌症的經濟負擔
  • 孤兒藥指定和法律規章的認證

第6章 產品研發線

第7章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各類型市場區隔

  • 癌細胞單克隆抗體
  • 免疫查核點抑制劑
  • 癌症疫苗
  • 非特定免疫療法

第9章 各地區市場市場區隔

  • 各地區市場
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第10章 推動市場的要素

  • 癌症罹患率上升
  • 癌細胞單克隆抗體需求擴大
  • 患者支援計劃
  • 有前途的開發平台

第11章 促進要素的影響

第12章 市場課題

  • 主力藥物的專利失效
  • 不充分的診斷與篩檢
  • 高開發成本
  • 副作用風險
  • 嚴格的法律規章

第13章 促進要素與課題的影響

第14章 市場課題

  • 癌症的認識提高
  • 標靶治療及聯合治療的登場
  • 生技仿製藥的登場
  • 策略性聯盟

第15章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2015年
  • Amgen
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck
  • 武田藥品工業株式會社
  • 其他值得注意的供應商

第16章 附錄

第17章 關於Technavio

圖表

目錄
Product Code: IRTNTR8400

About Cancer Immunotherapies

Cancer immunotherapy works by enhancing the innate powers of the immune system. This has better chances of successfully fighting cancer for a long period. Also, immunotherapies have fewer side effects and can treat different types of cancer. Cancer immunotherapies make up nearly 50% of the cancer drugs market.

Technavio's analysts forecast the global cancer immunotherapies market to grow at a CAGR of 15.17% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global cancer immunotherapies market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of cancer immunotherapies used to treat cancer.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Cancer Immunotherapies Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Amgen
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck
  • Takeda Pharmaceuticals

Other Prominent Vendors

  • AbbVie
  • ADC Therapeutics
  • Agensys
  • Astellas
  • AstraZeneca
  • Bayer
  • Biogen
  • Biotech Pharmaceutical
  • Boehringer-Ingelheim
  • Celgene
  • Celldex Therapeutics
  • Chugai Pharmaceutical
  • CTI Biopharma
  • Daiichi Sankyo
  • Eli Lilly
  • Fortress Biotech
  • Genmab
  • Immunomedics
  • Intas Pharmaceuticals
  • Janssen Biotech
  • Kyowa Hakko Kirin
  • MedImmune
  • Morphotek
  • Neovii Biotech
  • Novartis
  • OncoMed Pharmaceuticals
  • Pfizer
  • Sanofi
  • Seattle Genetics
  • Spectrum Pharmaceuticals
  • TG Therapeutics
  • XBiotech

Market driver

  • Increase in demand for cancer monoclonal antibodies
  • For a full, detailed list, view our report

Market challenge

  • Patent expiry of top-selling drugs
  • For a full, detailed list, view our report

Market trend

  • Emergence of targeted and combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Overview of cancer immunotherapies

  • Epidemiology
  • Spending on cancer
  • Cost of cancer treatment
  • Reimbursement policies
  • Economic burden of cancer
  • Orphan drug designation and regulatory approvals

PART 06: Pipeline portfolio

  • Anticipated number of products with single and multi-indications by 2020

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by type

  • Cancer monoclonal antibodies
  • Clinical trials of cancer monoclonal antibodies
  • Immune checkpoint inhibitors
  • Cancer vaccines
  • Non-specific immunotherapies
  • Global cancer monoclonal antibodies market
  • Global cancer vaccines market
  • Global immune checkpoint inhibitors market
  • Global non-specific immunotherapies market

PART 09: Geographical segmentation

  • Global cancer immunotherapies market by geography 2015-2020
  • Cancer immunotherapies market in Americas
  • Cancer immunotherapies market in EMEA
  • Cancer immunotherapies market in APAC

PART 10: Market drivers

  • Increase in prevalence of cancers
  • Increase in demand for cancer monoclonal antibodies
  • Patient assistance programs
  • Promising pipeline

PART 11: Impact of drivers

PART 12: Market challenges

  • Patent expiry of top-selling drugs
  • Poor diagnosis and screening
  • High developmental costs
  • Risk of side-effects
  • Stringent regulations

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Increase in cancer awareness
  • Emergence of targeted and combination therapies
  • Emergence of biosimilars
  • Strategic alliances

PART 15: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • Amgen
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck
  • Takeda Pharmaceuticals1
  • Other prominent vendors

PART 16: Appendix

  • List of abbreviations

PART 17: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Cancer immunotherapies in global cancer drugs market
  • Exhibit 03: Global incidence of cancer by type 2015
  • Exhibit 04: Global mortality by cancer type 2015
  • Exhibit 05: Estimated numbers of male and female cancer survivors by age in US 2014
  • Exhibit 06: Spending on cancer by distribution channels 2013
  • Exhibit 07: Annual treatment cost per patient for cancer immunotherapies 2014
  • Exhibit 08: Average cost of surgeries associated with cancer ($ millions) 2014
  • Exhibit 09: National reimbursement of cancer drugs by countries 2014
  • Exhibit 10: US FDA Orphan drug designations and approvals for cancer immunotherapies
  • Exhibit 11: EU orphan drug designations and approvals for cancer immunotherapies
  • Exhibit 12: Key events in cancer immunotherapies, discovery, and approvals
  • Exhibit 13: Timeline of some cancer immunotherapies
  • Exhibit 14: Phase III pipeline molecules for global cancer monoclonal antibodies market
  • Exhibit 15: Phase II pipeline molecules for global cancer monoclonal antibodies market
  • Exhibit 16: Phase I pipeline molecules for global cancer monoclonal antibodies market
  • Exhibit 17: Pipeline molecules for global immune checkpoint inhibitors market
  • Exhibit 18: Phase III pipeline molecules for global cancer vaccines market
  • Exhibit 19: Near-launch immuno-oncology pipeline assets
  • Exhibit 20: Global cancer immunotherapies market 2015-2020 ($ billions)
  • Exhibit 21: Factors influencing global cancer immunotherapies market
  • Exhibit 22: Five forces analysis
  • Exhibit 23: Global cancer immunotherapies market by type 2015
  • Exhibit 24: Timeline for approvals of cancer monoclonal antibodies by US FDA
  • Exhibit 25: Clinical trials of cancer monoclonal antibodies by development phase
  • Exhibit 26: Status of clinical trials of cancer monoclonal antibodies
  • Exhibit 27: Global cancer immunotherapies market by type of cancer immunotherapies 2015
  • Exhibit 28: Global cancer immunotherapies market by type of cancer immunotherapies 2015-2020 ($ billions)
  • Exhibit 29: Global cancer monoclonal antibodies market 2015-2020 ($ billions)
  • Exhibit 30: Key drivers and challenges of global cancer monoclonal antibodies market
  • Exhibit 31: Global cancer vaccines market 2015-2020 ($ billions)
  • Exhibit 32: Global cancer vaccines market by application 2015
  • Exhibit 33: Key drivers and challenges of global cancer vaccines market
  • Exhibit 34: Global immune checkpoint inhibitors market 2015-2020 ($ billions)
  • Exhibit 35: Key drivers and challenges for global immune checkpoint inhibitors market
  • Exhibit 36: Global non-specific immunotherapies market 2015-2020 ($ billions)
  • Exhibit 37: Global cancer immunotherapies market by geography 2015
  • Exhibit 38: Global cancer immunotherapies market revenue by geography 2015-2020 ($ billions)
  • Exhibit 39: Cancer immunotherapies market in Americas 2015-2020 ($ billions)
  • Exhibit 40: Cancer immunotherapies market in EMEA 2015-2020 ($ billions)
  • Exhibit 41: Cancer immunotherapies market in APAC 2015-2020 ($ billions)
  • Exhibit 42: Global incidence of cancer 2015 and 2020 in millions
  • Exhibit 43: Impact of drivers
  • Exhibit 44: Patent expiries of major cancer monoclonal antibodies by 2020
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Expected combination regimen launches in oncology
  • Exhibit 47: Top cancer immunotherapies based on sales 2014 ($ billions)
  • Exhibit 48: YoY Sales comparison of top drugs 2011-2014 ($ billions)
  • Exhibit 49: Cancer immunotherapy companies by origin country
  • Exhibit 50: Amgen: YoY growth and revenue generated from net product sales of Xgeva 2011-2014 ($ millions)
  • Exhibit 51: Amgen: YoY growth and revenue generated from net product sales of Prolia 2011-2014 ($ millions)
  • Exhibit 52: Amgen: YoY growth and revenue generated from net product sales of Vectibix worldwide excluding Japan 2011-2014 ($ millions)
  • Exhibit 53: Amgen: YoY growth and revenue of Vectibix in US 2012-2014 ($ millions)
  • Exhibit 54: Amgen: YoY growth and revenue of Vectibix in ROW 2012-2014 ($ millions)
  • Exhibit 55: Amgen: Key takeaways
  • Exhibit 56: Bristol-Myers Squibb: Segmentation by revenue 2014
  • Exhibit 57: Bristol-Myers Squibb: Revenue of oncology products by category 2014
  • Exhibit 58: Bristol-Myers Squibb: YoY growth and revenue generated from net product sales of Yervoy 2011-2014 ($ millions)
  • Exhibit 59: Bristol-Myers Squibb: YoY growth and revenue of Erbitux in US, Canada, and Japan 2010-2014 ($ millions)
  • Exhibit 60: Bristol-Myers Squibb: Key takeaways
  • Exhibit 61: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of MabThera/Rituxan 2011-2014 ($ billions)
  • Exhibit 62: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2011-2014 ($ billions)
  • Exhibit 63: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Herceptin 2011-2014 ($ billions)
  • Exhibit 64: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in US 2013-2014 ($ billions)
  • Exhibit 65: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in EU 2013-2014 ($ billions)
  • Exhibit 66: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in Japan 2013-2014 ($ millions)
  • Exhibit 67: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Perjeta 2012-2014 ($ millions)
  • Exhibit 68: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2014 ($ millions)
  • Exhibit 69: F. Hoffmann-La Roche: Key takeaways
  • Exhibit 70: GlaxoSmithKline: YOY growth and revenue of Arzerra 2012-2014 ($ millions)3
  • Exhibit 71: GlaxoSmithKline: YOY growth and revenue of Cervarix 2012-2014 ($ millions)3
  • Exhibit 72: GlaxoSmithKline: Key takeaways
  • Exhibit 73: Merck: YoY growth and revenue of Gardasil 2012-2014 ($ billions)6
  • Exhibit 74: Merck: YoY growth and revenue generated from net product sales of Erbitux, excluding US, Canada, and Japan 2011-2014 ($ billions
  • Exhibit 75: Merck: YOY growth and revenue of Erbitux in Europe 2012-2014 ($ millions)
  • Exhibit 76: Merck: YOY growth and revenue of Erbitux in emerging markets 2012-2014 ($ millions)
  • Exhibit 77: Merck: YOY growth and revenue of Erbitux in ROW 2012-2014 ($ millions)
  • Exhibit 78: Merck: Region-wise revenues of Erbitux 2012-2014 ($ millions)
  • Exhibit 79: Merck: Key takeaways
  • Exhibit 80: Takeda Pharmaceuticals: YoY growth and revenue generated from net product sales of Adcetris ($ millions)
  • Exhibit 81: Takeda Pharmaceuticals: YoY growth and revenue of Vectibix in Japan ($ millions)
  • Exhibit 82: Takeda Pharmaceuticals: Key takeaways
Back to Top